A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

NCT07111013 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Dry Eye Disease

Interventions

DRUG: Lifitegrast/perfluorohexyloctane (PFHO)

Sponsor

Bausch & Lomb Incorporated